{"id":542946,"date":"2021-05-12T19:08:01","date_gmt":"2021-05-12T19:08:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=542946"},"modified":"2021-05-12T19:08:01","modified_gmt":"2021-05-12T19:08:01","slug":"communityacquired-bacterial-pneumonia-cabp-market-analysis-market-size-epidemiology-leading-companies-and-therapies-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/communityacquired-bacterial-pneumonia-cabp-market-analysis-market-size-epidemiology-leading-companies-and-therapies-delveinsight_542946.html","title":{"rendered":"Community-Acquired Bacterial Pneumonia (CABP) Market Analysis, Market Size, Epidemiology, Leading Companies And Therapies | DelveInsight"},"content":{"rendered":"
\"Community-Acquired<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Community-Acquired Bacterial Pneumonia (CABP) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Community-Acquired Bacterial Pneumonia (CABP), historical and forecasted epidemiology as well as the Community-Acquired Bacterial Pneumonia (CABP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n

DelveInsight has launched a new report on “Community-acquired Bacterial Pneumonia (CABP) – Market Insights, Epidemiology, and Market Forecast-2030<\/a><\/strong><\/p>\n

DelveInsight’s “Community-acquired Bacterial Pneumonia (CABP) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>″ report deliver an in-depth understanding of the  Community-acquired Bacterial Pneumonia (CABP), historical and forecasted epidemiology as well as the  Community-acquired Bacterial Pneumonia (CABP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

    \n
  1. \n

    A prospective population-based cohort study estimated that approximately 5.6 million cases of CAP were reported annually in the United States with an annual age-adjusted incidence of 649 patients hospitalized with CAP\/100,000 adults, which corresponded to 1,591,825 annual adult CAP hospitalizations during the study period from 2014 to 2016.<\/p>\n<\/li>\n

  2. \n

    According to the book, approximately 3,370,000 cases of CAP are reported annually in the European Union with 1 million hospitalizations. Furthermore, the adult incidence of CAP in Europe ranges from 1.7–11.6 cases\/1,000 people\/year<\/p>\n<\/li>\n

  3. \n

    As per a study, there were approximately 1.9 million new CAP cases that occurred every year in Japan with nearly 70% of cases being reported in the >65 age group.<\/p>\n<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

    1. Community-acquired Bacterial Pneumonia (CABP) market report covers a descriptive overview and comprehensive insight of the Community-acquired Bacterial Pneumonia (CABP) epidemiology and Community-acquired Bacterial Pneumonia (CABP) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

    2. The Community-acquired Bacterial Pneumonia (CABP) market report provides insights on the current and emerging therapies.<\/p>\n

    3. Community-acquired Bacterial Pneumonia (CABP) market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/p>\n

    4. The Community-acquired Bacterial Pneumonia (CABP) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Community-acquired Bacterial Pneumonia (CABP) market.<\/p>\n

    Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/community-acquired-bacterial-pneumonia-cabp-market<\/span><\/a>
    <\/a><\/strong><\/p>\n

    Community-acquired Bacterial Pneumonia (CABP): Overview<\/strong><\/p>\n

    Community-acquired bacterial pneumonia (CABP) is a common, acute, severe infection of the lung parenchyma. It is a major cause of mortality in adults in Asia. It is one of the most frequent respiratory illnesses among various infections triggering sepsis.<\/p>\n

    The key players involved in Community-acquired Bacterial Pneumonia (CABP) market:<\/strong><\/p>\n

      \n
    1. \n

      Paratek Pharmaceuticals<\/p>\n<\/li>\n

    2. \n

      Melinta Therapeutics<\/p>\n<\/li>\n<\/ol>\n

      The launch of the emerging therapies is expected to significantly impact the  Community-acquired Bacterial Pneumonia (CABP) treatment scenario in the upcoming years:-<\/strong><\/p>\n

      Drug covered<\/strong><\/p>\n

        \n
      1. \n

        Nuzyra<\/p>\n<\/li>\n

      2. \n

        Baxdela<\/p>\n<\/li>\n<\/ol>\n

        Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/community-acquired-bacterial-pneumonia-cabp-market<\/span><\/a><\/strong><\/p>\n

        Table of Contents<\/strong><\/p>\n

        1. Report Introduction<\/p>\n

        2. Executive Summary<\/p>\n

        3. SWOT analysis<\/p>\n

        4. Community-acquired Bacterial Pneumonia (CABP) Patient Share (%) Overview at a Glance<\/p>\n

        5. Community-acquired Bacterial Pneumonia (CABP) Market Overview at a Glance<\/p>\n

        6. Community-acquired Bacterial Pneumonia (CABP) Disease Background and Overview<\/p>\n

        7. Community-acquired Bacterial Pneumonia (CABP) Epidemiology and Patient Population<\/p>\n

        8. Country-Specific Patient Population of Community-acquired Bacterial Pneumonia (CABP)<\/p>\n

        9. Community-acquired Bacterial Pneumonia (CABP) Current Treatment and Medical Practices<\/p>\n

        10. Unmet Needs<\/p>\n

        11. Community-acquired Bacterial Pneumonia (CABP) Emerging Therapies<\/p>\n

        12. Community-acquired Bacterial Pneumonia (CABP) Market Outlook<\/p>\n

        13. Country-Wise Community-acquired Bacterial Pneumonia (CABP) Market     Analysis (2017–2030)<\/p>\n

        14. Market Access and Reimbursement of Therapies<\/p>\n

        15. Market drivers<\/p>\n

        16. Market barriers<\/p>\n

        17. Appendix<\/p>\n

        18. Community-acquired Bacterial Pneumonia (CABP) Report Methodology<\/p>\n

        19. DelveInsight Capabilities<\/p>\n

        20. Disclaimer<\/p>\n

        21. About DelveInsight<\/p>\n

        Related Reports:<\/strong><\/p>\n

        Community-acquired Bacterial Pneumonia (CABP)- Pipeline Insights, 2021<\/strong><\/p>\n

        “Community-acquired Bacterial Pneumonia (CABP) Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the  Community-acquired Bacterial Pneumonia (CABP) market. A detailed picture of the  Community-acquired Bacterial Pneumonia (CABP) pipeline landscape is provided, which includes the disease overview and  Community-acquired Bacterial Pneumonia (CABP) treatment guidelines.<\/p>\n

        Community-acquired Bacterial Pneumonia (CABP) – Epidemiology Forecast to 2030<\/strong><\/p>\n

        DelveInsight’s ‘Community-acquired Bacterial Pneumonia (CABP) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Community-acquired Bacterial Pneumonia (CABP) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

        Media Contact<\/span>
        Company Name:<\/strong>         DelveInsight Business Research LLP<\/a>
        Contact Person:<\/strong> Kritika Rehani
        Email:<\/strong>         Send Email<\/a>
        Phone:<\/strong> 9193216187
        Address:<\/strong>304 S. Jones Blvd #2432
        City:<\/strong> Las Vegas
        State:<\/strong> Nevada
        Country:<\/strong> United States
        Website:<\/strong>         https:\/\/www.delveinsight.com\/<\/a><\/p>\n

        <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

        DelveInsight Business Research LLP DelveInsight’s “Community-Acquired Bacterial Pneumonia (CABP) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Community-Acquired Bacterial Pneumonia (CABP), historical and forecasted epidemiology as well as the Community-Acquired Bacterial Pneumonia (CABP) market … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-542946","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542946","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=542946"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542946\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=542946"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=542946"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=542946"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}